- NDA assigned a Target Action Date of February 25, 2026 - ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Australians progressing the work of a Nobel prize-winning chemist have developed a superbug-­destroying protein using ...

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable marke ...

Researchers at the University of Colorado Boulder have created a new way to build and control tiny particles that can move ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Shares of Cogent Biosciences were higher after the company disclosed what it called positive top-line results from a recent trial of its treatment for certain types of mastocytosis, a rare disorder in ...

Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China: Beijing, Shanghai Friday, July 4, 2025, 13:00 Hrs [ ...

A new report from congressional researchers examines the state of law around a federal statute that prohibits gun possession ...